Ken Griffin’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$156K Buy
+14,300
New +$174K ﹤0.01% 12537
2026
Q2
– Sell
-11,300
Closed -$59.6K – 14752
2026
Q1
$59.6K Sell
11,300
-3,500
-24% -$19.3K ﹤0.01% 12336
2025
Q4
$90K Buy
+14,800
New +$94.8K ﹤0.01% 11723
2025
Q2
– Sell
-2,600
Closed -$7.33K – 14853
2025
Q1
$7.33K Sell
2,600
-2,400
-48% -$11.7K ﹤0.01% 13695
2024
Q4
$34.4K Buy
5,000
+3,000
+150% +$38.7K ﹤0.01% 12747
2024
Q3
$36.4K Buy
+2,000
New +$37.2K ﹤0.01% 12250

Other funds holding SLN

Ken Griffin's SLN Position: Q3 2026 in Review

Ken Griffin increased its Silence Therapeutics (SLN) stake by 113% in Q3 2026, buying an estimated $18.2M and bringing the position to 2,825,601 shares worth $30.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Ken Griffin first reported a position in SLN in Q2 2022 and has held it in 13 quarters since. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Ken Griffin held 2,825,601 shares of Silence Therapeutics worth $30.9M as of Q3 2026.
  • Ken Griffin bought 1,495,976 Silence Therapeutics shares in Q3 2026, an estimated $18.2M.
  • Silence Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q3 2026, its #2070 holding.
  • Ken Griffin first reported a position in Silence Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.